Clinical Trials Logo

Endstage Renal Disease clinical trials

View clinical trials related to Endstage Renal Disease.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT03020303 Recruiting - Clinical trials for Endstage Renal Disease

Aldosterone bloCkade for Health Improvement EValuation in End-stage Renal Disease

ACHIEVE
Start date: July 7, 2017
Phase: Phase 3
Study type: Interventional

Individuals receiving dialysis are at risk of heart failure and heart related death. There is an urgent need for treatments that reduce the risk of these problems in patients that require dialysis. Spironolactone is a pill used to prevent heart failure and related deaths in patients that do not require dialysis. It works by blocking a hormone (aldosterone) in your body that causes high blood pressure and can damage the heart. Although spironolactone is very effective in patients that do not require dialysis, we do not know if spironolactone is effective in dialysis patients. Our research will help determine if spironolactone reduces heart failure and heart related deaths in dialysis patients. The purpose of this study is to determine if spironolactone reduces death or hospitalization for heart failure and is well tolerated in patients that require dialysis.

NCT ID: NCT02957877 Recruiting - Clinical trials for Endstage Renal Disease

LMWH Infusion as Anticoagulation for Home HD

Start date: March 2016
Phase: Phase 4
Study type: Interventional

There is a lack of data in the literature about the use of low-molecular weight heparin (LMWH) as anticoagulation for nocturnal home hemodialysis (NHHD). This study aims to evaluate the efficacy and safety of LMWH, administered by infusion method, as compared to unfractionated heparin as anticoagulation for NHHD treatment.